Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Adults who are overweight and have weight-related health conditions
See if youre eligible to join Mochi Health today
Hubbard SR, Hendrickson WA, Lambright DG, Boxer SG
Serum IGF-1 levels were significantly lower in the lower protein group, independent of other factors like body weight and body fat (30)
Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options
In clinical trials, average weight loss was approximately 1015% of body weight with semaglutide and 1522% with tirzepatide over 6872 weeks when combined with lifestyle changes
